

This is a promotional symposium organised by Merck on behalf of the Merck–Pfizer Alliance and is intended for healthcare professionals based in the UK only.

To access the Prescribing Information of BAVENCIO (avelumab), please click [here](#).

BAVENCIO (avelumab) is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression free following platinum-based chemotherapy.<sup>1</sup>

*This document is intended for electronic viewing only.*

# A CHANGING STANDARD OF CARE FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (UC): A DEEP DIVE INTO FIRST-LINE MAINTENANCE THERAPY

Friday 17 June 2022 | Time: 13:15–14:00

UK Oncology Forum 2022,  
International Convention Centre (ICC) Belfast

Join Professor Syed Hussain and Dr Simon Crabb, two leading UC experts in the UK, to explore the importance of overall survival of BAVENCIO® (avelumab) – the first and only NICE recommended (subject to certain conditions) immunotherapy option for first-line maintenance therapy in adult patients with advanced UC who have not progressed following first-line platinum-based chemotherapy.



## AGENDA

13:15	<b>Welcome and introduction</b>	<b>Professor Syed Hussain</b> <i>Professor and Consultant in Medical Oncology, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK</i>
13:20	<b>First-line maintenance versus second-line treatment: what is the difference?</b>	<b>Professor Syed Hussain</b>
13:35	<b>Maintenance therapy with BAVENCIO® (avelumab): a case study</b>	<b>Dr Simon Crabb</b> <i>Associate Professor in Medical Oncology at the University of Southampton and Associate Clinical Director of the Southampton Clinical Trials Unit, Southampton, UK</i>
13:45	<b>Audience Q&amp;A</b>	<b>Dr Simon Crabb and Professor Syed Hussain</b>
13:55	<b>Closing remarks</b>	<b>Professor Syed Hussain</b>
14:00	<b>Meeting close</b>	

We look forward to welcoming you to this symposium.

**Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Merck Serono Limited on 0208 818 7373 (email: [medinfo.uk@merckgroup.com](mailto:medinfo.uk@merckgroup.com)).**

NICE, National Institute for Health and Care Excellence; UC, urothelial carcinoma.

Reference

1. BAVENCIO (avelumab). SPC (GB: [www.medicines.org.uk](http://www.medicines.org.uk); NI: [www.emcmedicines.com/en-gb/northernireland](http://www.emcmedicines.com/en-gb/northernireland) accessed May 2022).

Links to external websites are provided as a resource to the viewer. Merck and Pfizer accept no responsibility for the content or services of the linked site other than the information or other materials relating to Merck or Pfizer medicines or business which Merck or Pfizer has provided or reviewed.

AVEBL-00057 | Date of preparation: May 2022